[The effect of benzbromarone on hyperlipidemia in gout].

It is well known that triglycerides and cholesterol are often increased in gout. In 50% of the patients with hyperuricemia and in 40% of the patients with gout hyperlipidemia is found. K. Kŭnev has found in his former studies that the treatment with the drug Desuric leads to a decrease of cholesterol and other lipids in the blood. The follow up of 38 men with proved gout, mean age 45 years and mean duration of the disease 5 years, established an increase mainly of endogenous triglycerides and cholesterol. Benzbromarone treatment, 50-100 mg daily, led to a parallel decrease of serum lipids and uric acid. This allows benzbromarone to be recommended for the treatment of hyperlipidemia in gout which will lead to a decrease of the vascular complications and mortality in gout.